Oslo University Hospital, Ullevaal
Oslo, 0450, Norway
NCT Number: NCT04118608
Rhabdomyolysis is a potentially life-threatening syndrome characterized by breakdown of skeletal muscle, and leakage of intracellular substances such as myoglobin and creatine kinase (CK) into the circulation. The aetiological spectrum of rhabdomyolysis is extensive, and the clinical spectrum varies from a transient subclinical increase in CK activity to acute kidney injury (AKI) as a serious complication. There are no large prospective studies and only a few retrospective studies on rhabdomyolysis.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Oslo, 0450, Norway
Rhabdomyolysis is a potentially life-threatening syndrome characterized by breakdown of skeletal muscle, and leakage of intracellular substances such as myoglobin and creatine kinase (CK) into the circulation. The aetiological spectrum of rhabdomyolysis is extensive, and the clinical spectrum varies from a transient subclinical increase in CK activity to acute kidney injury (AKI) as a serious complication. There are no large prospective studies and only a few retrospective studies on rhabdomyolysis.
The project will give much needed information about incidence, aetiologies and the clinical course of rhabdomyolysis. The main objective will be to study rhabdomyolysis with focus on the development of AKI and how laboratory values can guide treatment, and thus act as basis for guidelines. More knowledge is needed about rhabdomyolysis and long-term kidney injury, and the study will aim to identify a risk population for later kidney injury, thus being able to refer this group to follow-up and prevent further injury. On the other hand, exercise-induced rhabdomyolysis patients are probably hospitalized more than necessary these days, and over-treatment could be prevented if better guidelines were obtained. The possible cardiotoxicity of myoglobin needs further study, and would benefit the patient group but also fill a knowledge gap for the clinicians. Therefore, this project will ideally obtain new knowledge for the health services, potentially improve existing practice and fill important knowledge gaps.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
No intervention
Time frame: Change of creatinine from baseline (KDIGO 2012 guidelines) through hospitalization (average 1 week)
AKI will be defined according to KDIGO 2012 guidelines
Time frame: 3 months
Change in kreatinine and/or eGFR. CKD classifications followed KDIGO stages I-V
Time frame: During hospitalization (average 1 week)
Other complications including death
Time frame: Change of creatinine from baseline (KDIGO 2012 guidelines) through hospitalization (average 1 week)
Risk of AKI (see above) can be predicted based on this ratio
Time frame: Through hospitalization (average 1 week)
Increased Troponin T levels and findings on echocardiography with strain and in some cardiac IMR
Time frame: Through hospitalization (average 1 week)
See if risk of AKI (see above) can be predicted based on this
Oslo University Hospital
Other
Acronym: RhabdoGuide
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07433127
Critical Illness, Crush Injuries
Erzurum, Turkey (Türkiye)
View Trial DetailsNCT07352319
Athletes, Exercise-induced Muscle Damage
Jeddah, Saudi Arabia
View Trial DetailsNCT01976936
Brain Diseases, Cardiovascular Diseases
Los Angeles, California, United States
View Trial DetailsNCT01544231
Acute Kidney Failure, Acute Kidney Injury
Nîmes, Gard, France
View Trial Details